DK1572199T3 - Pyrazol-derivater som modulatorer af hepatocyt-vækst-faktor (scatter factor) aktivitet - Google Patents
Pyrazol-derivater som modulatorer af hepatocyt-vækst-faktor (scatter factor) aktivitetInfo
- Publication number
- DK1572199T3 DK1572199T3 DK03814306.1T DK03814306T DK1572199T3 DK 1572199 T3 DK1572199 T3 DK 1572199T3 DK 03814306 T DK03814306 T DK 03814306T DK 1572199 T3 DK1572199 T3 DK 1572199T3
- Authority
- DK
- Denmark
- Prior art keywords
- factor
- modulators
- activity
- hepatocyte growth
- pyrazole derivatives
- Prior art date
Links
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 title 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 title 2
- 150000003217 pyrazoles Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43553302P | 2002-12-21 | 2002-12-21 | |
| US10/740,708 US7192976B2 (en) | 2002-12-21 | 2003-12-18 | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| PCT/US2003/040917 WO2004058721A2 (en) | 2002-12-21 | 2003-12-19 | Pyrazole derivatives modulators of hepatocyte growth factor (scatter factor) activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1572199T3 true DK1572199T3 (da) | 2014-02-03 |
Family
ID=32685400
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10011181.4T DK2292227T3 (en) | 2002-12-21 | 2003-12-19 | Pyrazole derivatives as modulators of hepatocyte growth factor (scatter factor) activity |
| DK03814306.1T DK1572199T3 (da) | 2002-12-21 | 2003-12-19 | Pyrazol-derivater som modulatorer af hepatocyt-vækst-faktor (scatter factor) aktivitet |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10011181.4T DK2292227T3 (en) | 2002-12-21 | 2003-12-19 | Pyrazole derivatives as modulators of hepatocyte growth factor (scatter factor) activity |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US7192976B2 (enExample) |
| EP (2) | EP1572199B1 (enExample) |
| JP (3) | JP5160019B2 (enExample) |
| CN (1) | CN1747730B (enExample) |
| AU (1) | AU2003301224C1 (enExample) |
| CA (1) | CA2511199C (enExample) |
| DK (2) | DK2292227T3 (enExample) |
| HU (1) | HUE030700T2 (enExample) |
| IL (1) | IL169316A (enExample) |
| WO (1) | WO2004058721A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7192976B2 (en) | 2002-12-21 | 2007-03-20 | Angion Biomedica Corporation | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| US20110230407A1 (en) * | 2005-03-14 | 2011-09-22 | Alexander Yuzhakov | Hepatocyte growth factor pathway activators in demyelinating diseases and central nervous system trauma |
| US7879898B1 (en) | 2006-02-14 | 2011-02-01 | Angion Biomedica Corp. | Hepatocyte growth factor pathway activators in chronic obstructive pulmonary disease |
| EP2313093A4 (en) * | 2008-07-10 | 2012-03-28 | Angion Biomedica Corp | METHOD AND COMPOSITIONS FOR LOW-MOLECULAR MODULATORS OF THE HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY |
| WO2010068287A2 (en) * | 2008-12-11 | 2010-06-17 | Angion Biomedica Corp. | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| WO2011006072A2 (en) * | 2009-07-10 | 2011-01-13 | Northwestern University | Cardioprotective role of hepatic cells and hepatocyte secretory factors in myocardial ischemia |
| US20120190668A1 (en) * | 2009-08-12 | 2012-07-26 | Oehlen Lambertus J W M | Enhancement of cellular transplantation using small moleucle modulators of hepatocyte growth factor (scatter factor) activity |
| CN110269856A (zh) | 2010-03-30 | 2019-09-24 | 维颂公司 | 多取代芳族化合物作为凝血酶的抑制剂 |
| JP2014509297A (ja) * | 2010-10-05 | 2014-04-17 | アンジオン バイオメディカ コーポレイション | 肝細胞増殖因子（散乱因子）活性の小分子モジュレーターの使用方法 |
| JP6173298B2 (ja) * | 2011-04-02 | 2017-08-02 | ワシントン ステート ユニバーシティ | 治療薬としての肝細胞増殖因子模倣体 |
| WO2012151349A1 (en) | 2011-05-03 | 2012-11-08 | Liu Shu Q | Neuroprotection by hepatic cells and hepatocyte secretory factors |
| UY34200A (es) * | 2011-07-21 | 2013-02-28 | Bayer Ip Gmbh | 3-(fluorovinil)pirazoles y su uso |
| RU2678830C2 (ru) | 2013-03-15 | 2019-02-04 | Версеон Корпорейшн | Полизамещенные ароматические соединения в качестве ингибиторов сериновых протеаз |
| KR20150130405A (ko) | 2013-03-15 | 2015-11-23 | 베르선 코포레이션 | 트롬빈의 억제제로서의 할로게노피라졸 |
| JP2017528486A (ja) | 2014-09-17 | 2017-09-28 | ヴァーセオン コーポレイション | セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物 |
| HK1246164A1 (zh) | 2015-02-27 | 2018-09-07 | Verseon Corporation | 作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物 |
| KR20220004083A (ko) | 2019-04-11 | 2022-01-11 | 앤지온 바이오메디카 코포레이션 | (e)-3-[2-(2-티에닐)비닐]-1h-피라졸의 고체 형태 |
| WO2021087392A1 (en) * | 2019-10-31 | 2021-05-06 | Angion Biomedica Corp. | Improving renal function after kidney transplantation |
| WO2021183774A1 (en) * | 2020-03-12 | 2021-09-16 | Angion Biomedica Corp. | Treating acute respiratory distress |
| EP4228626A2 (en) * | 2020-10-14 | 2023-08-23 | Angion Biomedica Corp. | Preparation of terevalefim and formulations thereof |
| CA3196582A1 (en) * | 2020-11-02 | 2022-05-05 | Leen Kawas | Bicyclic compounds and uses thereof for the treatment of diseases |
| WO2022217070A1 (en) * | 2021-04-09 | 2022-10-13 | Angion Biomedica Corp. | Hgf/sf mimetic compounds |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE138770C (enExample) * | ||||
| JPS48713Y1 (enExample) | 1967-12-19 | 1973-01-09 | ||
| JPS48713U (enExample) | 1971-05-22 | 1973-01-08 | ||
| DD138770A1 (de) * | 1978-09-20 | 1979-11-21 | Juergen Liebscher | Verfahren zur herstellung von 5-styryl-pyrazolen und ihren vinylogen |
| JPH02193994A (ja) | 1989-01-23 | 1990-07-31 | Kyowa Hakko Kogyo Co Ltd | ピリダジノン誘導体 |
| FR2669633B1 (fr) * | 1990-11-23 | 1993-01-22 | Adir | Nouveaux derives de la benzoselenazolinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| US5837676A (en) | 1993-10-18 | 1998-11-17 | Long Island Jewish Medical Center | Use of scatter factor to enhance angiogenesis |
| US6498144B1 (en) | 1993-10-18 | 2002-12-24 | North Shore - Long Island Jewish Research Institute | Use of scatter factor to enhance angiogenesis |
| US5476076A (en) * | 1994-12-06 | 1995-12-19 | Zhou; Zhishan | Internal combustion piston engine utilizing interference movable fit technology |
| JPH11288112A (ja) | 1998-04-06 | 1999-10-19 | Mitsubishi Paper Mills Ltd | 電子写真感光体 |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| WO2001034650A1 (en) * | 1999-11-09 | 2001-05-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services | Hgf-sf monoclonal antibody combinations |
| EP1355921A2 (en) | 2000-06-29 | 2003-10-29 | North Shore-Long Island Jewish Health System | Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof |
| US6589997B2 (en) | 2001-06-29 | 2003-07-08 | North Shore-Long Island Jewish Health System | Small-molecule modulators of hepatocyte growth factor/scatter factor activities |
| US6610726B2 (en) | 2001-06-29 | 2003-08-26 | North Shore-Long Island Jewish Research Institute | Compositions and agents for modulating cellular proliferation and angiogenesis |
| WO2004009599A1 (en) | 2002-07-19 | 2004-01-29 | Targacept, Inc. | Five-membered heteroaromatic olefinic azacyclic compounds, pharmaceutical compositions containing them and their use as inhibitors of ncotinic cholinergic receptors |
| US7192976B2 (en) * | 2002-12-21 | 2007-03-20 | Angion Biomedica Corporation | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
-
2003
- 2003-12-18 US US10/740,708 patent/US7192976B2/en not_active Expired - Lifetime
- 2003-12-19 CN CN2003801095507A patent/CN1747730B/zh not_active Expired - Fee Related
- 2003-12-19 AU AU2003301224A patent/AU2003301224C1/en not_active Ceased
- 2003-12-19 EP EP03814306.1A patent/EP1572199B1/en not_active Expired - Lifetime
- 2003-12-19 JP JP2004563939A patent/JP5160019B2/ja not_active Expired - Fee Related
- 2003-12-19 DK DK10011181.4T patent/DK2292227T3/en active
- 2003-12-19 CA CA2511199A patent/CA2511199C/en not_active Expired - Lifetime
- 2003-12-19 DK DK03814306.1T patent/DK1572199T3/da active
- 2003-12-19 WO PCT/US2003/040917 patent/WO2004058721A2/en not_active Ceased
- 2003-12-19 EP EP10011181.4A patent/EP2292227B1/en not_active Expired - Lifetime
- 2003-12-19 HU HUE10011181A patent/HUE030700T2/en unknown
-
2004
- 2004-12-29 US US11/025,373 patent/US7265112B2/en not_active Expired - Lifetime
- 2004-12-29 US US11/024,615 patent/US7250437B2/en not_active Expired - Lifetime
-
2005
- 2005-06-21 IL IL169316A patent/IL169316A/en active IP Right Grant
-
2007
- 2007-08-13 US US11/891,618 patent/US8580834B2/en not_active Expired - Fee Related
-
2010
- 2010-08-23 JP JP2010186703A patent/JP5755417B2/ja not_active Expired - Fee Related
-
2013
- 2013-10-07 US US14/047,907 patent/US9663471B2/en not_active Expired - Fee Related
-
2015
- 2015-01-30 JP JP2015016424A patent/JP2015078246A/ja active Pending
-
2019
- 2019-01-11 US US16/245,373 patent/US20190382348A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1572199T3 (da) | Pyrazol-derivater som modulatorer af hepatocyt-vækst-faktor (scatter factor) aktivitet | |
| DK2025670T3 (da) | Anvendelse af 3-phenylthio-1H-indol-1-eddikesyre-derivater som modulatorer af CRTh2-receptor aktivitet | |
| DK1656345T3 (da) | Cykliske derivater som modulatorer af chemokinreceptoraktivitet | |
| NO20220690A1 (no) | Stabil krystall av 4-oxoquinolinforbindelse | |
| DK1490064T3 (da) | Substituerede pyridinoner som modulatorer af p38 MAP kinase | |
| DK1562589T3 (da) | Diaminotriazoler der er nyttige som inhibitorer af proteinkinaser | |
| DK1532145T3 (da) | Pyrazolpræparater der er anvendelige som inhibitorer af GSK-3 | |
| DK1686999T3 (da) | Pyrazolderivater som inhibitorer af receptortyrosinkinaser | |
| SE0701538L (sv) | Azaspiroalkanderivat som hämmare av metalloproteaser | |
| NO20050426L (no) | Arylkarbonylderivater som terapeutiske midler | |
| DK1480644T3 (da) | Heterocykliske forbindelser, der er aktive som inhibitorer af beta-lactamaser | |
| NO20043158L (no) | Substituerte kinazolinderivater som inhibitorer av aurorakinaser | |
| NO20043793L (no) | Nikotinamidderivater anvendelige som PDE4 inhibitorer | |
| NO20035766L (no) | Aminonikotinatderivater som glukokinase (GLK) modulatorer | |
| DE50210090D1 (de) | Substituierte phenylderivate | |
| DK1638928T3 (da) | N-alkynyl-2-(substituerede aryloxy)alkylthio-amidderivater som fungicider | |
| DK1549638T3 (da) | Indol-3-carboxamider som glucokinase (GK) aktivatorer | |
| NO20053215D0 (no) | Pyrazolderivater med anvendelse som COX-1-inhibitorer. | |
| IL181450A0 (en) | Modulators of hepatocyte growth factor activator | |
| DK1492789T3 (da) | Tropanderivater som CCR5-modulatorer | |
| NO20050665L (no) | Pyrrolidonderivater som MAOE inhibitoere | |
| DK1691607T3 (da) | Anvendelse af N-arylhydrazinderivater til bekæmpelse af skadedyr | |
| DK1401828T3 (da) | N-Formylhydroxylaminforbindelser som inhibitorer af PDF | |
| DK1516540T3 (da) | Anvendelse af vitamin D-forbindelser | |
| DK1600441T3 (da) | Krystallinsk form af elrcanidipinhydrochlorid til anvendelse som et antihypertensivt middel |